XKRX:069620 (Korea (the Republic of))
Â
Ordinary Shares
â‚©
117600.00
(-1.92%)
Dec 11
Business Description
Daewoong Pharmaceutical Co Ltd
ISIN : KR7069620003
Share Class Description:
XKRX:069620: Ordinary SharesCompare
Compare
Traded in other countries / regions
069620.Korea IPO Date
2002-11-01Description
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.18 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.72 | |||||
| Debt-to-EBITDA | 3.1 | |||||
| Interest Coverage | 16.92 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.29 | |||||
| Beneish M-Score | -2.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.7 | |||||
| 3-Year EBITDA Growth Rate | 37 | |||||
| 3-Year EPS without NRI Growth Rate | 130.7 | |||||
| 3-Year Book Growth Rate | 9.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.33 | |||||
| 9-Day RSI | 34.45 | |||||
| 14-Day RSI | 35.33 | |||||
| 3-1 Month Momentum % | 10.47 | |||||
| 6-1 Month Momentum % | 36.71 | |||||
| 12-1 Month Momentum % | 31.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | |||||
| Quick Ratio | 0.61 | |||||
| Cash Ratio | 0.2 | |||||
| Days Inventory | 128.52 | |||||
| Days Sales Outstanding | 36.89 | |||||
| Days Payable | 47.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.3 | |||||
| Shareholder Yield % | -6.26 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.23 | |||||
| Operating Margin % | 9.74 | |||||
| Net Margin % | 7.31 | |||||
| FCF Margin % | -12.61 | |||||
| ROE % | 13.44 | |||||
| ROA % | 5.7 | |||||
| ROIC % | 7.37 | |||||
| 3-Year ROIIC % | 15.92 | |||||
| ROC (Joel Greenblatt) % | 21.63 | |||||
| ROCE % | 12.07 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.03 | |||||
| Forward PE Ratio | 11.53 | |||||
| PE Ratio without NRI | 12.36 | |||||
| PEG Ratio | 0.76 | |||||
| PS Ratio | 0.95 | |||||
| PB Ratio | 1.66 | |||||
| Price-to-Tangible-Book | 2.77 | |||||
| Price-to-Operating-Cash-Flow | 31.87 | |||||
| EV-to-EBIT | 12.83 | |||||
| EV-to-EBITDA | 9.64 | |||||
| EV-to-Revenue | 1.29 | |||||
| EV-to-FCF | -10.42 | |||||
| Price-to-GF-Value | 0.94 | |||||
| Price-to-Projected-FCF | 2.81 | |||||
| Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.49 | |||||
| Price-to-Graham-Number | 1.23 | |||||
| Earnings Yield (Greenblatt) % | 7.79 | |||||
| FCF Yield % | -13.2 | |||||
| Forward Rate of Return (Yacktman) % | 17.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Daewoong Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 1,416,626.109 | ||
| EPS (TTM) (â‚©) | 9031 | ||
| Beta | 0.3 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.06 | ||
| Volatility % | 46.05 | ||
| 14-Day RSI | 35.33 | ||
| 14-Day ATR (â‚©) | 5446.107156 | ||
| 20-Day SMA (â‚©) | 125795 | ||
| 12-1 Month Momentum % | 31.29 | ||
| 52-Week Range (â‚©) | 100100 - 164400 | ||
| Shares Outstanding (Mil) | 11.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Daewoong Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Daewoong Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Daewoong Pharmaceutical Co Ltd Frequently Asked Questions
What is Daewoong Pharmaceutical Co Ltd(XKRX:069620)'s stock price today?
The current price of XKRX:069620 is â‚©117600.00. The 52 week high of XKRX:069620 is â‚©164400.00 and 52 week low is â‚©100100.00.
When is next earnings date of Daewoong Pharmaceutical Co Ltd(XKRX:069620)?
The next earnings date of Daewoong Pharmaceutical Co Ltd(XKRX:069620) is .
Does Daewoong Pharmaceutical Co Ltd(XKRX:069620) pay dividends? If so, how much?
Daewoong Pharmaceutical Co Ltd(XKRX:069620) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers